Stocks
AVANIR TECHNOLOGIES INCAVNR
YHDHealthcareBiotechnology
A specialty pharmaceutical company focused on developing and commercializing therapies for central nervous system disorders. Its lead product, Nuedexta, treats pseudobulbar affect, and the company has a pipeline of CNS candidates. Investors track AVNR for its commercial execution and regulatory milestones.
Congressional Interest in AVANIR TECHNOLOGIES INC (AVNR)
1 member of Congress has disclosed 4 trades in AVANIR TECHNOLOGIES INC (AVNR), a Healthcare company. The buy/sell breakdown shows 0 purchases versus 4 sales, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
4
Unique Politicians
1
Buys
0
Sells
4
Who in Congress Is Trading AVNR?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2017-05-24 | MICHAEL T. MCCAUL | sell | $1K-$15K |
| 2017-05-24 | MICHAEL T. MCCAUL | sell | $1K-$15K |
| 2017-05-22 | MICHAEL T. MCCAUL | sell | $1K-$15K |
| 2017-05-17 | MICHAEL T. MCCAUL | sell | $1K-$15K |